81 results
Page 2 of 5
8-K
a796hzm66
28 Jun 22
Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer
4:02pm
8-K
EX-99.1
l9z63vq
28 Jun 22
Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer
4:02pm
8-K
EX-99.1
pgq amd3jc8quwo
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-99.3
4phw52lffw10r hk
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-99.1
d63gk 0h3lw0tk
12 May 22
Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments
4:52pm
8-K
EX-99.1
n8rapvda
24 Mar 22
Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments
4:21pm
8-K
EX-99.1
zr3o7n1gvhpc
17 Feb 22
Yumanity Therapeutics Exploring Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring
8:37am
8-K
EX-99.1
mxkucn9745okrpdtkm83
19 Jan 22
Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739
7:42am
8-K
EX-99.1
cyf1r
15 Nov 21
Yumanity Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
7:42am
8-K
EX-99.2
47npz47j
10 Nov 21
Regulation FD Disclosure
7:12am
8-K
EX-99.1
gga0pz
16 Aug 21
Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants
7:21am
8-K
EX-99.1
ryut6um4d
12 Aug 21
Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
4:21pm
8-K
EX-99.1
o0ef7d2g
13 May 21
Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Developments
4:00pm